NCT01744925

Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR

An Open-label,Randomized,Controlled Study to Evaluate the Safety and Efficacy for Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to evaluate the safety and efficacy of icotinib at routine dose and higher dose as second-line treatment in non-small cell lung cancer patients with epidermal growth factor receptor of wild type.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Icotinib of routine dose	Icotinib: 125mg, oral administration, three times per day.
DRUG	Icotinib of high dose	Icotinib: 375mg, oral administration, three times per day.

Timeline

• Start date: 2012-10-01
• Primary completion: 2017-11-01
• Completion: 2017-12-01
• First posted: 2012-12-07
• Last updated: 2017-02-07

Locations

1 site across 1 country: China